IL-17 Inhibitors Archives

Taltz receives U.S. FDA approval for nr-axSpA

Approvals, FDA, FDA/Regulatory, IL-17 Inhibitors, Inflammation, Non-Radiographic Axial Spondyloarthritis (nr-axSpA), Supplemental Biologics License Application

The U.S. Food and Drug Administration approved a supplemental Biologics License Application for Eli Lilly and Company’s Taltz (ixekizumab) injection 80 mg/mL for the treatment of active non-radiographic axial spondyloarthritis (nr-axSpA) in patients with objective signs of inflammation.

June 1, 2020/by PR Newswire

Lilly’s Taltz Hits Mark in Phase III Inflammatory Study

Axial Spondyloarthritis, Clinical Trials, Disease-Modifying Antirheumatic Drugs (DMARDs), IL-17 Inhibitors, Inflammatory Diseases, Monoclonal Antibodies, Non-Radiographic Axial Spondyloarthritis (nr-axSpA), R&D

Eli Lilly is planning to seek another regulatory approval for Taltz after the medication hit the primary and secondary endpoints in a Phase III study for non-radiographic axial spondyloarthritis.

November 12, 2019/by BioSpace